Chemopreventive effects of the dietary histone deacetylase inhibitor tributyrin alone or in combination with vitamin A during the promotion phase of rat hepatocarcinogenesis

Journal of Nutritional Biochemistry

Volumn 23, Issue 8, 2012, Pages 860-866

  de Conti, Aline ^a   Kuroiwa Trzmielina, Joice ^a   Horst, Maria A ^a   Bassoli, Bruna K ^a   Chagas, Carlos E A ^a   Purgatto, Eduardo ^a   Cavalher, Felicia P ^b   Camargo, Anamaria A ^b   Jordão, Alceu A ^a   Vannucchi, Hélio ^a   Scolastici, Clarissa ^a   Ong, Thomas P ^a   Moreno, Fernando S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

Author keywords

Chemoprevention; Epigenetic; Hepatocarcinogenesis; Tributyrin; Vitamin A

Indexed keywords

BUTYRIC ACID; CELLULAR RETINOL BINDING PROTEIN 1; DIETHYLNITROSAMINE; PROTEIN P21; RETINOID; RETINOL; RETINOL PALMITATE; TRIBUTYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL COUNT; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; GENE SILENCING; HISTONE ACETYLATION; LIVER CARCINOGENESIS; LIVER CELL; MALE; MICRODISSECTION; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CHEMOPREVENTION; HEPATOCYTES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; PRECANCEROUS CONDITIONS; RATS; RATS, WISTAR; RHO GTP-BINDING PROTEINS; TRIGLYCERIDES; VITAMIN A;

ANIMALIA; RATTUS;

EID: 84864000201     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.04.010     Document Type: Article

References (54)

1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
2. Shimizu M., Takai K., Moriwaki H. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid × receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 2009, 100:369-374.
3. Hauser A.T., Jung M. Targeting epigenetic mechanisms: potential of natural products in cancer chemoprevention. Planta Med 2008, 74:1593-1601.
4. Dashwood R.H., Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 2007, 17:363-369.
5. Link A., Balaguer F., Goel A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol 2010, 80:1771-1792.
6. Chen J., Xu X. Diet, epigenetic, and cancer prevention. Adv Genet 2010, 71:237-255.
7. Pajak B., Orzechowski A., Gajkowska B. Molecular basis of sodium butyrate- dependent proapoptotic activity in cancer cells. Adv Med Sci 2007, 52:838-888.
8. Miller A.A., Kurschel E., Osieka R., Schmidt C.G. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987, 23:1283-1287.
9. Avivi-Green C., Polak-Charcon S., Madar Z., Schwartz B. Apoptosis cascade proteins are regulated in vivo by high intracolonic butyrate concentration: correlation with colon cancer inhibition. Oncol Res 2000, 12:83-95.
10. Egorin M.J., Yuan Z.M., Sentz D.L., Plaisance K., Eiseman J.L. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother Pharmacol 1999, 43:445-453.
11. Lai D.T., Mackenzie A.D., O'Connor C.J., Turner K.W. Hydrolysis characteristics of bovine milk fat and monoacid triglycerides mediated by pregastric lipase from goats and kids. J Dairy Sci 1997, 80:2249-2257.
12. Parodi P.W. Cows' milk fat components as potential anticarcinogenic agents. J Nutr 1997, 127:1055-1060.
13. Kuroiwa-Trzmielina J., de Conti A., Scolastici C., Pereira D., Horst M.A., Purgatto E., et al. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug. Int J Cancer 2009, 124:2520-2527.
14. Altucci L., Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001, 1:181-193.
15. Okuno M., Kojima S., Matsushima-Nishiwaki R., Tsurumi H., Muto Y., Friedman S.L., et al. Retinoids in cancer chemoprevention. Curr Cancer Drug Targets 2004, 4:285-298.
16. Fonseca E.M.A.V., Chagas C.E., Mazzantini R.P., Heidor R., Ong T.P., Moreno F.S. All- trans and 9-cis retinoic acids, retinol and beta-carotene chemopreventive activities during the initial phases of hepatocarcinogenesis involve distinct actions on glutathione S-transferase positive preneoplastic lesions remodeling and DNA damage. Carcinogenesis 2005, 26:1940-1946.
17. Moreno F.S., S-Wu T., Naves M.M., Silveira E.R., Oloris S.C., da Costa M.A., et al. Inhibitory effects of beta-carotene and vitamin A during the progression phase of hepatocarcinogenesis involve inhibition of cell proliferation but not alterations in DNA methylation. Nutr Cancer 2002, 44:80-88.
18. Johanning G.L., Piyathilake C.J. Retinoids and epigenetic silencing in cancer. Nutr Rev 2003, 61:84-89.
19. Trosko J.E. The role of stem cells and gap junctions as targets for cancer chemoprevention and chemotherapy. Biomed Pharmacother 2005, 59:S326-S331.
20. De los Santos M., Zambrano A., Aranda A. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol Cancer Ther 2007, 6:1425-1432.
21. Savickiene J., Treigyte G., Magnusson K.E., Navakauskiene R. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors. Ann N Y Acad Sci 2009, 1171:321-333.
22. Kuendgen A., Schmid M., Schlenk R., Knipp S., Hildebrandt B., Steidl C., et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106:112-119.
23. Semple-Roberts E., Hayes M.A., Armstrong D., Becker R.A., Racz W.J., Farber E. Alternative methods of selecting rat hepatocellular nodules resistant to 2-acetylaminofluorene. Int J Cancer 1987, 40:643-645.
24. Higgins G.M., Anderson R.M. Experimental pathology of the liver: restoration of the liver of the white rat following partial surgical removal. Arch Pathol 1931, 12:186-202.
25. Squire R.A., Levitt M.H. Report of a workshop on classification of specific hepatocellular lesions in rats. Cancer Res 1975, 35:3214-3223.
26. Wood G.A., Sarma D.S., Archer M.C. Resistance to the promotion of glutathione S- transferase 7-7-positive liver lesions in Copenhagen rats. Carcinogenesis 1999, 20:1169-1175.
27. Stinchcombe S., Buchmann A., Bock K.W., Schwarz M. Inhibition of apoptosis during 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated tumor promotion in rat liver. Carcinogenesis 1995, 16:1271-1275.
28. Ong T.P., Heidor R., de Conti A., Dagli M.L.Z., Moreno F.S. Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase. Carcinogenesis 2005, 27:1194-1203.
29. Goldsworthy T.L., Fransson-Steen R., Maronpot R.R. Importance of and approaches to quantification of hepatocyte apoptosis. Toxicol Pathol 1996, 24:24-35.
30. Mazzantini R.P., de Conti A., Moreno F.S. Persistent and remodeling hepatic preneoplastic lesions present differences in cell proliferation and apoptosis, as well as in p53, Bcl-2 and NF-κB pathways. J Cell Biochem 2008, 103:538-546.
31. Stahl M., Sundquist A.R., Hanusch M., Schwarz W., Sie H. Separation of β-carotene and lycopene geometrical isomers in biological samples. Clin Chem 1993, 39:810-814.
32. Murray M., Butler A.M., Martini R. Inhibition of microsomal 17 hydroxysteroid oxyreduction activities in rat liver by all-trans-, 9-cis-,and 13-cis-retinoic acid. Biochim Biophys Acta 1994, 1222:227-233.
33. Harsch M., Bendrat K., Hofmeier G., Branscheid D., Niendorf A.A. new method for histological microdissection utilizing an ultrasonically oscillating needle demonstrated by differential mRNA expression in human lung carcinoma tissue. Am J Pathol 2001, 158:1985-1990.
34. Esteller M., Guo M., Moreno V., Peinado M.A., Capella G., Galm O. Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res 2002, 62:5902-5905.
35. Sambrook J., Russel D.W. Molecular cloning: a laboratory manual 2001, Cold Spring Harbor Laboratory, New York. 1st ed.
36. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996, 93:9821-9826.
37. Husmann M., Hoffmann B., Stump D.G., Chytil F., Pfahl M. A retinoic acid response element from the rat CRBPI promoter is activated by an RAR/RXR heterodimer. Biochem Biophys Res Commun 1992, 30:1558-1564.
38. William W.N., Heymach J.V., Kim E.S., Lippman S.M. Molecular targets for cancer chemoprevention. Nat Ver Drug Discov 2009, 8:213-225.
39. Andersen J.B., Loi R., Perra A., Factor V.M., Ledda-Columbano G.M., Columbano A. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology 2010, 51:1401-1409.
40. Farber E., Sarma D.S. Hepatocarcinogenesis: a dynamic cellular perspective. Lab Invest 1987, 56:4-22.
41. Wattenberg L.W. Inhibition of tumorigenesis in animals. IARC Sci Publ 1996, 139:151-158.
42. Mann K.K., Rephaeli A., Colosimo A.L., Diaz Z., Nudelman A., Levovich I., et al. A retinoid/ butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis. Mol. Cancer Res 2003, 1:903-912.
43. Epping M.T., Wang L., Plumb J.A., Lieb M., Gronemeyer H., Brown R., et al. A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2007, 104:17777-17782.
44. Tatebe H., Shimizu M., Shirakami Y., Sakai H., Yasuda Y., Tsurumi H., et al. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett 2009, 285:210-217.
45. Richon V.M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 1996, 93:5705-5708.
46. Bach K.E., Serena A., Canibe N., Juntunen K.S. New insight into butyrate metabolism. Proc Nutr Soc 2003, 62:81-86.
47. Furr H.C., Clifford A.J., Smith L.M., Olson J.A. The effect of dietary fatty acid composition on liver retinyl ester (vitamin A ester) composition in the rat. J Nutr 1989, 119:581-585.
48. De Luca L.M., Brugh M., Silverman-Jones C.S. Retinyl palmitate, retinyl phosphate, and dolichyl phosphate of postnuclear membrane fraction from hepatoma, host liver, and regenerating liver: marginal vitamin A status of hepatoma tissue. Cancer Res 1984, 44:224-232.
49. Adachi S., Moriwaki H., Muto Y., Yamada Y., Fukutomi Y., Shimazaki M., et al. Reduced retinoid content in hepatocellular carcinoma with special reference to alcohol consumption. Hepatology 1991, 14:776-780.
50. Arapshian A., Bertran S., Kuppumbatti Y.S., Nakajo S., Mira-y-Lopez R., Epigenetic C.R.B.P. downregulation appears to be an evolutionarily conserved (human and mouse) and oncogene-specific phenomenon in breast cancer. Mol Cancer 2004, 27:3-13.
51. Bavik C., Ward S.J., Ong D.E. Identification of a mechanism to localize generation of retinoic acid in rat embryos. Mech Dev 1997, 69:155-167.
52. Kanematsu T., Kawano T., Takenaka K., Matsumata T., Sugimachi K., Kuwano M. Levels of vitamin A and cellular retinol binding protein in human hepatocellular carcinoma and adjacent normal tissue. Nutr Cancer 1989, 12:311-319.
53. Boorjian S., Tickoo S.K., Mongan N.P., Yu H., Bok D., Rando R.R., et al. Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer. Clin Cancer Res 2004, 10:3429-3437.
54. Spurling C.C., Suhl J.A., Boucher N., Nelson C.E., Rosenberg D.W., Giardina C. The short chain fatty acid butyrate induces promoter demethylation and reactivation of RARβ2 in colon cancer cells. Nutr Cancer 2008, 60:692-702.